Automated Quality Control: Accelerating Lot Release with PCR Assays

Automated quality control has moved to the center of biopharmaceutical manufacturing strategy, and the clearest evidence is the displacement of weeks-long culture-based tests by rapid polymerase chain reaction (PCR) assays that return equivalent safety data in hours. Where traditional mycoplasma detection once required up to 28 days of culture-based incubation, quantitative real-time PCR (qPCR) and digital droplet PCR (ddPCR) now deliver results within a single working day. This enables manufacturers to compress lot-release timelines, reduce batch hold costs, and respond faster to contamination events before they propagate through production.

Lot release bottlenecks: the cost of culture-based quality control

Biopharmaceutical lot release is governed by a battery of required safety and quality tests that a batch must pass before it can be shipped or administered. For decades, the two most time-limiting tests have been mycoplasma detection and sterility testing, both of which rely on culture-based compendial methods that require extended incubation periods to confirm the absence of contamination.

Mycoplasma contamination is a persistent concern in biopharmaceutical production. Contamination rates in established cell culture systems have been reported between 15% and 35% in certain populations, according to published industry estimates, making reliable detection a non-negotiable release criterion. The compendial methods described in the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP) require organisms to grow on or in culture media or indicator cell systems before they can be detected, a process that can take up to 28 calendar days using standard methods. For monoclonal antibody manufacturers producing material with long shelf lives, a 28-day hold is inconvenient but manageable. For cell therapy developers producing patient-specific autologous products with much shorter shelf lives, this approach is operationally incompatible with clinical delivery.

Sterility testing presents a comparable challenge. The compendial sterility test framework requires a minimum incubation period of 14 days to confirm the absence of viable microorganisms, with no interim result available until the full incubation period is complete. Even with risk-based provisional release strategies, the manufacturing organization must carry analytical and regulatory risk until final confirmation is received.

PCR assays for mycoplasma lot release: regulatory requirements and performance thresholds

The regulatory basis for replacing culture methods with nucleic acid amplification techniques (NAAT) is well established. The EP chapter 2.6.7 has recognized NAAT-based mycoplasma detection methods since 2008, requiring validation against a sensitivity threshold of 10 colony-forming units (CFU) per milliliter, or fewer than 100 genome copies per milliliter, of test sample. A substantially revised EP 2.6.7 (version 12.2), published in late 2025 and effective from April 1, 2026, formalizes this framework further, harmonizing requirements with the Japanese Pharmacopoeia and USP chapters. This revision explicitly recognizes NAAT methods as equivalent to culture-based approaches when appropriate validation is demonstrated.

For lot release applications, manufacturers must demonstrate that a PCR assay meets defined criteria for specificity, sensitivity, robustness, and comparability to compendial methods. Validated qPCR methods using hydrolysis probe-based detection formats can achieve limits of detection at or below the 10 CFU/mL threshold across the full range of species likely to contaminate bioproduction cell lines. A 2025 mycoplasma qPCR study described the development of a pharmacopeia-compliant qPCR approach capable of rapid, specific mycoplasma identification from biopharmaceutical samples, demonstrating that carefully designed primer and hydrolysis probe systems can achieve the specificity and sensitivity targets regulators require.

Once validated and filed with the relevant regulatory authority, PCR assays have received widespread acceptance for lot release use. The Food and Drug Administration (FDA) accepted the first commercially available PCR-based mycoplasma test for the release testing of a biopharmaceutical product in 2012, establishing a precedent that has since been replicated across multiple therapeutic modalities and jurisdictions. This regulatory track record reduces the uncertainty for manufacturers initiating their own PCR validation programs and filing supplemental applications to replace compendial methods.

It also highlights the benefits of PCR-based approaches compared to traditional culture-based methods (Table 1).

Table 1: Comparison of culture-based and PCR-based mycoplasma detection methods for biopharmaceutical lot release.

Residual host cell DNA lot release testing with ddPCR

Residual host cell DNA (resDNA) is a process-related impurity that must be measured and controlled in every biologic drug product. Regulatory guidance establishes that resDNA levels should generally not exceed 10 nanograms per dose for products derived from continuous cell lines, with more stringent limits applied to certain cell and gene therapy products. The resDNA specification is not only a safety requirement, but also a process performance indicator: consistently low resDNA demonstrates that downstream purification is operating within validated parameters.

Conventional qPCR methods for resDNA quantification require reference standard curves and make amplification efficiency assumptions that introduce variability, particularly when applied to complex formulated matrices. ddPCR addresses these limitations by partitioning each sample into approximately 20,000 nanoliter-scale oil-encapsulated droplets, running individual PCR reactions in each partition, and counting positive droplets to calculate absolute copy number without a standard curve. This approach is more tolerant of PCR inhibitors present in formulation excipients and purification process intermediates, and it produces more reproducible results across operators and instrument runs.

A 2023 peer-reviewed study published in Human Gene Therapy demonstrated the feasibility of ddPCR for quantifying residual HEK293 host cell DNA in recombinant adeno-associated virus preparations, confirming sensitivity and precision suitable for lot release applications. The FDA has also validated ddPCR for resDNA quantification in biologics produced in E. coli, demonstrating that extraction-free workflows can achieve detection limits 300-fold to 6,000-fold lower than the 10 ng/dose regulatory threshold, with accuracy and linearity meeting ICH criteria.

The expanding use of ddPCR for resDNA testing aligns with the broader application of real-time analytical technologies in bioprocessing, where the same principles of in-process measurement, sensitivity, and data integrity that govern inline sensors also apply to end-of-process quality testing.

PCR quality control method validation under ICH Q2(R2)

No PCR assay can be used for lot release without formal analytical method validation. The regulatory framework governing that validation is ICH Q2(R2), adopted in November 2023 and effective from June 2024. The revised guideline explicitly expanded its scope beyond the chromatographic methods that dominated its predecessor to address biological product testing methods, including NAAT.

Under ICH Q2(R2), a PCR-based quality control method intended for lot release must demonstrate specificity; limits of detection and quantitation; linearity across the relevant dynamic range; accuracy, expressed as recovery; precision at both repeatability and intermediate precision levels; and robustness under deliberate variations in assay conditions. For mycoplasma assays, comparability to compendial methods must also be established. These requirements are not unique to PCR, but the revised guideline provides clearer guidance on how to apply them to methods where amplification efficiency and matrix effects play a central role in method performance.

Tackling Bispecific Antibody Purification: A Polishing Case Study

Join this data-driven presentation to explore process development resin screening for bispecific antibody purification.
View Webinar

Advertisement

The validation package generated during method development becomes the basis for regulatory submission, whether as part of a new biologics license application, a supplemental filing to replace a compendial method, or a post-approval change submission. The ICH Q2(R2) guidance document published by the European Medicines Agency (EMA) is the authoritative reference for manufacturers undertaking these validation programs.

The effort required for PCR method validation is non-trivial, but it is a one-time investment that pays dividends across every subsequent manufacturing cycle. A validated mycoplasma qPCR assay that replaces a 28-day culture method eliminates weeks of batch hold time from every production run for the life of the product.

Automated quality control in cell and gene therapy manufacturing

Cell and gene therapy products present the sharpest case for automated quality control based on PCR. These products are typically manufactured in small, patient-specific batches with strict post-formulation windows before infusion is required. An autologous CAR T-cell therapy product, once formulated, must be administered within a narrow timeframe defined in the clinical release protocol; waiting 28 days for a mycoplasma result is not a delay, it is a categorical incompatibility with the manufacturing model.

In practice, cell and gene therapy lot release testing routinely incorporates PCR-based assays for mycoplasma detection, identity confirmation, and residual DNA quantification. Regulatory reviewers at the FDA, EMA, and other major authorities have accepted validated PCR methods for lot release across multiple cell and gene therapeutic modalities, including cell culture-based manufacturing and viral vector programs. Identity testing, which confirms that the manufactured product carries the intended genetic payload or cell surface phenotype, is frequently performed via PCR or quantitative PCR alongside flow cytometry-based marker analysis. For viral vector products such as adeno-associated virus and lentiviral vectors, qPCR and ddPCR are used for vector genome titer determination, a primary release criterion. These applications are examined in the context of the broader drug development characterization platforms, including the mass spectrometry and proteomics workflows that complement PCR-based assays across biologic development pipelines.

Automation of PCR testing further accelerates lot release by reducing manual handling, eliminating transcription errors, and generating audit-ready electronic records in compliance with 21 Code of Federal Regulations Part 11 requirements. Integrated automated platforms that perform nucleic acid extraction, PCR setup, amplification, and data analysis in a continuous closed workflow represent the operational realization of process analytical technology (PAT) principles in bioprocessing. Both share the goal of real-time, data-rich quality assurance, extending to end-of-process release criteria in the same way PAT sensors apply to upstream critical process parameters.

Automated PCR lot release testing as a prerequisite for modern biomanufacturing

The transition from culture-based testing to automated PCR-based quality control is one of the most consequential improvements available to biopharmaceutical manufacturers seeking to compress release timelines without compromising safety. The regulatory infrastructure supporting this transition is now well established, the validation pathways under ICH Q2(R2) are clearly defined, and the analytical performance of both qPCR and ddPCR platforms has been demonstrated across a wide range of biologic product types and manufacturing matrices.

For manufacturers evaluating the switch, the practical starting point is assay selection and matrix validation, followed by a formal comparability study against the compendial method to establish equivalent sensitivity and specificity. The investment in this validation, measured in months of development work, is recovered within a small number of production cycles through elimination of batch hold time, earlier lot disposition, and reduced warehouse carrying costs. For cell and gene therapy developers, where regulatory timelines and patient clinical schedules cannot tolerate a 28-day analytical delay, rapid, automated PCR-based quality control is not an optimization but a prerequisite.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.